Selling and marketing spending of Innovent Biologics 2019-2022
In 2022, the selling and marketing expenses of Chinese pharmaceutical firm Innovent Biologics Inc. amounted to 2.58 billion yuan, increasing by 40 million from the year prior. The core products of Innovent Biologics include anti-tumor medicines and drugs treating metabolic disorders and autoimmune diseases.